In contrast to these models, the severe UUO model resembling SSc, where all lysyl oxidase isoforms were elevated, pan-lysyl oxidase inhibition with PXS-5505 as potent anti-fibrotic therapeutic strategy was required and confirming previous data with BAPN [42]. Here, LOX is linked to systemic sclerosis.